description
Leukotrienes are made by cells of the immune system, mainly the mediators of inflammation like polymorphonuclear leukocytes, macrophages and mast cells. Cellular activation during inflammation leads to the translocation of both phospholipase A2 and : HS00336-MONOMER to the nuclear envelope. Phospholipase A2 releases arachidonic acid from the membrane and : HS00336-MONOMER transforms the arachidonic acid to the epoxide leukotriene A4 with the help of the 5-lipoxygenase activating protein (FLAP) . Leukotrienes are proinflammatory metabolites that activate and amplify both innate and adaptive immune responses. They also have roles in pathological immune responses, mediating contraction of bronchial smooth muscles and chemoattraction of lymphocytes. The enzymes in this pathway are ideal targets for therapeutic intervention in allergic responses . Leukotriene B4 (LTB4) is a potent chemoattractant, while LTC4 stimulates bronchial constriction in asthmatics. Enzymes in this biosynthetic pathway are also targets for cardiovascular therapies as is the regulatory protein FLAP, which has been linked to increased risk for myocardial infarction and stroke . The cysteinyl leukotrienes LTC4, LTD4 and LTE4 were originally dubbed "slow-reacting substance of anaphylaxis" for their ability to mediate slow and sustained contraction of smooth muscle

external resources
NCBI:545300
BIOCYC:HUMAN_PWY66-375
PUBMED:20097252
PUBMED:14770184
PUBMED:11729303

genes
ALOX5 , DPEP1 , LTA4H , LTC4S , DPEP2 ,